COVID-19: Rapid Antibody Screening & Saliva Testing

COVID-19 Screening Available to Residents of Bluffdale, Draper, Riverton, and Vineyard

Press Release
Published: May 15, 2020

The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.

Mayors from the participating communities released this joint statement about the project:

“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”

Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:

  • Wednesday, May 20 – Draper
  • Thursday, May 21 – Riverton
  • Tuesday, May 26 – Draper
  • Thursday, May 28 – Bluffdale
  • Friday, May 29 – Vineyard

Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.

Rapid Testing Utah for COVID19 Antibodies2

The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.

Mayors from the participating communities released this joint statement about the project:

“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”

Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:

  • Wednesday, May 20 – Draper
  • Thursday, May 21 – Riverton
  • Tuesday, May 26 – Draper
  • Thursday, May 28 – Bluffdale
  • Friday, May 29 – Vineyard

Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.

Rapid Testing Utah for COVID19 Antibodies2

FDA Authorized Saliva Testing will be used to Confirm Active COVID-19 Infection

In addition, RSS will randomly administer a saliva-based DNA test to some test subjects. Draper-based Spectrum Solutions manufactures the saliva tests that detect active COVID-19 infection, rather than detecting antibodies. Any person who tests positive for antibodies will also receive the saliva test to confirm active COVID-19 infection. The testing will be conducted in full compliance with FDA and CLIA requirements. The test results will not be diagnostic but are designed to provide valuable data about the COVID-19 infection rate. Check on the availability of diagnostic at-home COVID-19 testing options using saliva by visiting Spectrum’s website.

Spectrum Solutions SDNA-1000 Only EUA Approved Saliva Collection

© Spectrum Solutions™ SDNA-1000 Only EUA Authorized Saliva Collection Device for COVID-19 Testing | Photo Credit: Leslie Titus Bryant

Spectrum
in the News

Spectrum
in the News

About the Product

Innovative Engineering
SDNA-1000

Open-blister-pack-spectrum-saliva-dna-collection-device

Spectrum Solutions has manufactured over 10 million Saliva Collection devices for distribution worldwide. The SDNA-1000 Saliva Collection Device is Spectrum’s latest device, which will help to lead the saliva collection market in molecular and other diagnostic applications. This fit-for-purpose and technically superior whole saliva collection device has been engineered to reduce self-collection error, is bacteriostatic, and delivers the consistent high-quality, high-yield samples for any medical diagnostic or clinical research required application. The patented preservation solution stabilizes viral samples within the saliva matrix effectively reducing additional exposure-risks to health professionals. As a result, ensuring sample stability at a variety of temperatures that enable the primary sample to be shipped as well as easily stored in case repeat testing is required.

Now available and currently being used as a biosample collection option for viral DNA/RNA COVID-19 testing for hospital networks, health departments, and clinical research organizations ready to accept tens of thousands of samples per day for SARS-CoV-2 coronavirus testing and analysis. Spectrum does its product manufacturing of the SDNA-1000 saliva collection device in-house at their facility in Salt Lake City with the capacity, and proven scalability to meet the rapid growing need for COVID-19 testing devices.

Questions? Let’s Connect